Viewing Study NCT02757105


Ignite Creation Date: 2025-12-25 @ 3:23 AM
Ignite Modification Date: 2025-12-31 @ 5:09 PM
Study NCT ID: NCT02757105
Status: COMPLETED
Last Update Posted: 2018-08-28
First Post: 2016-04-27
Is Gene Therapy: True
Has Adverse Events: True

Brief Title: Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)
Sponsor: RedHill Biopharma Limited
Organization: